IL202996A0 - Anti-mcp-1 antibodies, compositions, methods and uses - Google Patents

Anti-mcp-1 antibodies, compositions, methods and uses

Info

Publication number
IL202996A0
IL202996A0 IL202996A IL20299609A IL202996A0 IL 202996 A0 IL202996 A0 IL 202996A0 IL 202996 A IL202996 A IL 202996A IL 20299609 A IL20299609 A IL 20299609A IL 202996 A0 IL202996 A0 IL 202996A0
Authority
IL
Israel
Prior art keywords
mcp
antibodies
compositions
methods
Prior art date
Application number
IL202996A
Other languages
English (en)
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of IL202996A0 publication Critical patent/IL202996A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
IL202996A 2007-06-29 2009-12-27 Anti-mcp-1 antibodies, compositions, methods and uses IL202996A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94698807P 2007-06-29 2007-06-29
PCT/US2008/068696 WO2009006359A2 (en) 2007-06-29 2008-06-30 Anti- mcp-1 antibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
IL202996A0 true IL202996A0 (en) 2011-08-01

Family

ID=40158715

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202996A IL202996A0 (en) 2007-06-29 2009-12-27 Anti-mcp-1 antibodies, compositions, methods and uses

Country Status (8)

Country Link
US (1) US20100254992A1 (enExample)
EP (1) EP2170387A4 (enExample)
JP (1) JP2011517548A (enExample)
CN (1) CN101827610A (enExample)
AU (1) AU2008269954A1 (enExample)
CA (1) CA2692392A1 (enExample)
IL (1) IL202996A0 (enExample)
WO (1) WO2009006359A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686008A1 (en) * 2011-03-15 2014-01-22 INSERM - Institut National de la Santé et de la Recherche Médicale Compositions and methods for inhibiting tumor development caused by chemotherapy induced senescence
CN110072883A (zh) 2016-09-28 2019-07-30 科巴公司 治疗性mots-c相关的肽
EP3773627A1 (en) 2018-03-27 2021-02-17 Cohbar Inc. Peptide-containing formulations
US11739142B2 (en) 2019-12-18 2023-08-29 Hoffmann-La Roche Inc. Bispecific anti-CCL2 antibodies
CN112358547A (zh) * 2020-09-30 2021-02-12 浙江大学 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用
AU2022295067A1 (en) * 2021-06-18 2023-12-21 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
CN118620076B (zh) * 2024-07-03 2024-12-17 武汉爱博泰克生物科技有限公司 用于检测鼠单核细胞趋化蛋白1的抗体和抗体对及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
US6696248B1 (en) * 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
JPH0967399A (ja) * 1995-08-30 1997-03-11 Mitsui Toatsu Chem Inc 抗ｍｃｐ−１ヒトモノクローナル抗体
PL209786B1 (pl) * 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds
RU2339647C2 (ru) * 2002-08-19 2008-11-27 Астразенека Аб Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение
CA2507080C (en) * 2002-11-27 2015-01-06 Biogen Idec Ma Inc. Humanized antibodies against monocyte chemotactic proteins
WO2006125201A2 (en) * 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
PE20061444A1 (es) * 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos

Also Published As

Publication number Publication date
CA2692392A1 (en) 2009-01-08
EP2170387A2 (en) 2010-04-07
WO2009006359A2 (en) 2009-01-08
WO2009006359A8 (en) 2009-12-30
EP2170387A4 (en) 2011-01-19
CN101827610A (zh) 2010-09-08
US20100254992A1 (en) 2010-10-07
JP2011517548A (ja) 2011-06-16
AU2008269954A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
IL187459A0 (en) Anti - mcp-1 antibodies, compositions, methods and uses
EP2043687A4 (en) ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
ZA201102081B (en) Engineered anti0il-13 antibodies,compositions,methods and uses
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
ZA201106118B (en) Anti-vegf antibody compositions and methods
EP1784425A4 (en) ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES
IL205355A0 (en) Anti- hepcidin antibodies and uses thereof
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
IL204930A0 (en) Human anti - amyloid antibodies, compositions, methods and uses
IL210643A0 (en) Anti-hepcidin-25 selective antibodies and uses thereof
EP2219458A4 (en) COMPOSITIONS AND METHOD FOR THE PRODUCTION OF ANTIBODIES
IL207164A0 (en) Folates, compositions and uses thereof
IL193392A0 (en) Influenza antibodies, compositions, and related methods
EP2205276A4 (en) ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
GB0706077D0 (en) Methods, Compositions and uses thereof
GB0601143D0 (en) Uses, methods and compositions
IL202996A0 (en) Anti-mcp-1 antibodies, compositions, methods and uses
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
EP2150818A4 (en) COMPOSITIONS AND METHOD FOR COMBINING REPORT ANTIBODIES
PL2262828T3 (pl) Kompozycje, sposoby i zestawy
ZA201101520B (en) Phenanthrenone compounds,compositions and methods
GB0812277D0 (en) Antibody and uses thereof
HK1141714A (en) Anti- mcp-1 antibodies, compositions, methods and uses
GB0723044D0 (en) Lyophillised antigen composition